Abstract
Purpose :
To evaluate the duration from onset of any retinopathy of prematurity (ROP) to type 1 ROP or AP-ROP at a single institution in Japan.
Methods :
Medical records of 578 infants who were screened from September 2009 to March 2016 in neonatal intensive care unit were reviewed. The first fundus examination was started at 29 or 30 weeks of postmenstrual age (PMA) or 3 weeks of chronologic age, whichever came later. Follow-up examinations were scheduled more than once a week if vascular extension was present within Zone I or posterior Zone II. The mean age at onset of any ROP, the mean age at treatment and the duration from onset to treatment were compared between infants with type 1 ROP and those with AP-ROP. Data were analyzed for 1 randomly selected eye for each infant.
Results :
Of 578 infants, 52 (8.9%) progressed to type 1 ROP and 32 (3.9%) to AP-ROP. The mean gestational age and birth weight were significantly decreased in infants with AP-ROP compared to those with type 1 ROP (p<0.0001, p<0.0001, respectively). There was no significant difference in the mean age at onset of any ROP between type 1 ROP (31.9±1.58 weeks PMA) and AP-ROP (31.2±0.92 weeks PMA, p=0.12). The age at treatment was, however, earlier in AP-ROP (32.0±1.18 weeks PMA) compared to type 1 ROP (35.3±2.5 weeks PMA, p<0.0001). Although the onset-to-treatment duration was 24.2±18.8 days in type 1 ROP, only 5.4±5.42 days in AP-ROP. Of 23 infants with AP-ROP, 3 (13%) required treatment on first examination day.
Conclusions :
The time course of progression was different between type 1 ROP and AP-ROP, whereas the initial diagnosis of onset was not. Our findings of progression pattern in ROP subtypes may help the management of optimal timing for ROP examinations. AP-ROP can progress rapidly within a week of onset, vigilant examinations may be necessary in the first week after day of initial diagnosed with any ROP.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.